BSX Stents OK'd for AMI Patients - Analyst Blog
February 24 2012 - 10:15AM
Zacks
Boston Scientific
Corporation (BSX) has received approval from the US Food
and Drug Administration ("FDA") for use of its Ion and Taxus
Liberete stents in patients experiencing an acute myocardial
infarction (“AMI”), commonly called a heart attack. These are thus
the only drug-eluting-stents (“DES”) in the US for treatment of
heart attack patients.
The FDA approval is based on
positive data from the HORIZONS-AMI trial, where 3,006 patients
were randomized to receive either DES or bare-metal stents (“BMS”)
for the treatment of AMI. It was observed that paclitaxel-eluting
stents were more effective to bare-metal stents. We expect Boston
Scientific to garner higher revenues from this approval as the new
indication accounts for approximately 10% of all coronary
interventions.
The latest development will
undeniably come to the aid of a huge patient population as,
according to estimates from the American Heart Association, death
by heart attack accounts for one out of every six deaths each year
in the U.S. There are more than 1.2 million new and recurrent cases
of heart attack each year, with approximately 34% succumbing to
death.
Over the past few quarters, Boston
Scientific has been working on expanding its portfolio of core
segments consisting of stents and defibrillators as these
businesses are witnessing several headwinds. The recently reported
quarter was no exception as global sales of coronary stent system
(within Interventional Cardiology), at $381 million, declined 6.8%
due to disappointing performance from both DES that declined 5.6%
to $356 million and BMS that dropped 21.8% to $25 million.
Given the headwinds currently at
play for Boston Scientific, the company has been undertaking
several strategic initiatives that included focus on emerging
markets, restructuring initiatives, among others. In this respect,
the company recently announced the first implants of a Teligen
implantable cardioverter defibrillator (“ICD”) in China that is
designed to treat sudden cardiac death.
In November last year, Boston
Scientific received approval from State Food and Drug
Administration (SFDA) for the Teligen franchise. With the world's
largest population in China, this region represents one of the
world's fastest-growing ICD markets, which is estimated to grow
more than 15% annually over the next five years.
Boston Scientific is not the only
company to eye the emerging markets. Major players in the MedTech
sector such as Medtronic (MDT) and St Jude
Medical (STJ) have also adopted a similar strategy to
counter a challenging top line.
Longer term, we have a Neutral
recommendation on Boston Scientific. The stock retains a Zacks #3
Rank (“Hold”) in the short term.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024